GCAR Announces the Discontinued Evaluation of Eritoran in REMAP-COVID
19 May 2022 //
BUSINESSWIRE
Eisai to involve jointly in COVID-19 drug discovery utilizing Eritoran and E6011
05 Oct 2020 //
BIOSPECTRUMASIA
Eisai to investigate eritoran in REMAP-COVID study
01 Jul 2020 //
CLINICALTRIALSARENA